These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12871022)

  • 1. Engineering regulatory elements for conditionally-replicative adeno-viruses.
    Haviv YS; Curiel DT
    Curr Gene Ther; 2003 Aug; 3(4):357-85. PubMed ID: 12871022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis.
    Nettelbeck DM
    Anticancer Drugs; 2003 Sep; 14(8):577-84. PubMed ID: 14501378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
    Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Armed replicating adenoviruses for cancer virotherapy.
    Cody JJ; Douglas JT
    Cancer Gene Ther; 2009 Jun; 16(6):473-88. PubMed ID: 19197323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
    Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
    Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
    Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
    Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells.
    Savontaus MJ; Sauter BV; Huang TG; Woo SL
    Gene Ther; 2002 Jul; 9(14):972-9. PubMed ID: 12085246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
    Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
    Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy.
    Li S; Ou M; Wang G; Tang L
    Appl Microbiol Biotechnol; 2016 Oct; 100(19):8325-35. PubMed ID: 27557721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
    Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
    Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
    Shashkova EV; Spencer JF; Wold WS; Doronin K
    Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses.
    Suzuki K; Alemany R; Yamamoto M; Curiel DT
    Clin Cancer Res; 2002 Nov; 8(11):3348-59. PubMed ID: 12429621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures.
    Banerjee NS; Rivera AA; Wang M; Chow LT; Broker TR; Curiel DT; Nettelbeck DM
    Mol Cancer Ther; 2004 Apr; 3(4):437-49. PubMed ID: 15078987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.
    van Beusechem VW; Mastenbroek DC; van den Doel PB; Lamfers ML; Grill J; Würdinger T; Haisma HJ; Pinedo HM; Gerritsen WR
    Gene Ther; 2003 Nov; 10(23):1982-91. PubMed ID: 14528322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.